Recognition follows National Academy of Medicine Healthy Longevity Grand Prize win and highlights Immunis' pioneering approach to restoring muscle function and advancing healthy aging

Immunis, Inc., a clinical-stage biotechnology company pioneering multi-active biologics to address age-related decline and promote healthspan, announced that it was named one of The Healthcare Technology Report's (HTR) "Top Biotech and Life Sciences Companies of 2026." This distinction acknowledges companies advancing medicine's most promising innovations and bringing breakthrough technologies closer to clinical use.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261110228127/en/

Immunis announced that it was named one of The Healthcare Technology Report's "Top Biotech and Life Sciences Companies of 2026."

This marks the company’s second year on the prestigious list of key innovators in scientific, regulatory and industry progress and builds on the recognition of Immunis last month as the National Academy of Medicine's Healthy Longevity Global Competition Grand Prize. Later this month, new preclinical data of Immunis’ investigational IMM01-STEM therapy will be presented by its Chief Science Officer, Dr. Tom Lane, at Obesity Week in Washington, D.C..

“Aging is a multi-system problem that requires a multi-active immunotherapy, one that can address the complex processes that contribute to chronic disease and age-related decline,” says Hans Keirstead, PhD, Chairman of the Board at Immunis. “Immunis has produced an immunotherapy that addresses what matters most to patients: mobility, strength, and independence.”

Immunis' lead investigational biologic, IMM01-STEM, is a first-in-class, multi-active secretome-based therapy designed to address the complex biological pathways associated with age-related muscle and metabolic decline. In a Phase 2 clinical research study of older adults with sarcopenic obesity, IMM01-STEM demonstrated preservation of muscle and improvements in gait speed, a clinically meaningful measure of mobility and physical function.

The Immunis team is advancing its clinical development program with plans for two confirmatory Phase 2b trials, supported by financing and expanded manufacturing capabilities designed to accelerate the development of IMM01-STEM. Immunis celebrates HTR’s recognition and will build on this momentum to pursue promising advances in regenerative medicine with real-world impact.

About Immunis

Immunis is a clinical-stage biotechnology company developing novel multi-active biologics designed to address age-related muscle and metabolic decline. Its lead investigational therapy, IMM01-STEM, leverages a proprietary secretome-based approach to target multiple biological pathways associated with aging and restore muscle function. Through rigorous clinical development and a focus on meaningful functional outcomes, Immunis aims to advance therapies that help people maintain mobility, independence, and quality of life as they age.

Cautionary Note Regarding Forward-Looking Statements

This communication contains statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as applicable. Forward-looking statements include, but are not limited to, statements regarding our plans, beliefs, expectations, and assumptions, as well as other statements that are not necessarily historical facts. You are cautioned that these forward-looking statements are only predictions and involve risks and uncertainties. Further, any forward-looking statement speaks only of the date as of which it is made, and we do not intend to update or revise any forward-looking statements. This communication also contains market data related to our business and industry, which includes projections that are based on several assumptions we believe are reasonable and most significant to the projections as of the date of this communication. If any of our assumptions prove to be incorrect, our actual results may significantly differ from our projections based on these assumptions. This communication is neither an offer to sell nor a solicitation of an offer to buy any of the securities described herein.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261110228127/en/

“Immunis has produced an immunotherapy that addresses what matters most to patients: mobility, strength, and independence.”